Giant Biogene Holding Co., Ltd. risk profile
27 Normal where most of the sector sits
Measured 21 October 2026 from 2367.HK's filed statements. Recomputed nightly.
27 (Normal), driven by Operating pressure at 64, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 59 | Elevated | Stable | Drawdown from the 52-week high — 42.1% |
| Operating pressure | 64 | Stretched | Easing | Costs outgrowing revenue — +4.9 percentage points |
| Cash conversion | 31 | Normal | Worsening | Cash conversion — 0.93x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA — -2.59x |
| Competitive position | 10 | Contained | Stable | R&D-intensity gap against peers — +0.4 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Consumer Defensive companies with a risk reading
Walmart Inc 51Costco Wholesale Corp 44Coca-Cola Company 39Procter & Gamble Company 30Philip Morris International Inc 24Nestle S.A. 46Nestlé S.A 47L'Oréal S.A. 38PepsiCo Inc 49Anheuser-Busch InBev SA/NV 36Unilever plc 45Unilever PLC 35
Financials, valuation and price history for Giant Biogene Holding Co., Ltd.